Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 6 of about 6   

Articles published

DVAX 23.57 +0.33 (1.42%)
price chart
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior ...
One of them is Dynavax Technologies (NASDAQ:DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
6 Stocks Trading Under $5 on Winning Streaks
Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): A clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.
Risk Vs. Reward Never Gets Old
Everything one needs for a wild ride in a biotech company. The reason I like ... Dynavax Technologies has a number of promising drugs, with HEPLISAVTM being their prize, as it treats Hepatitis B, which afflicts 350 million people worldwide.
Biodefense Industry - Market to Benefit from Federal Funding such as the BIO ...
7.2.1 Biodefense Contracts 31. 7.3 Bavarian Nordic 32. 7.3.1 Biodefense Contracts 32. 7.4 Cleveland BioLabs 33. 7.4.1 Biodefense Contracts 33.
Dendreon's Provenge: Under Attack Once Again
In last week's article, Huber asserted '…researchers analyzed some of the data [in the Phase 3 trial] differently from how the company told U.S. regulators they would." According to Begley, "[T]hat not only was a departure from scientific norms ...
Nokia (NYSE:NOK) Can Fix Apple Inc. (NASDAQ:AAPL)'s Mapping Problem, - (F ...
Ford Motor Company (NYSE:F)'s shares were up after analysts at Sterne Agee repeated their buy rating on the stock. In the last trading session, the stock's price moved -8.29% below its 200 day moving average, changing hands as low as $9.76 per share.